| 6.95 Data as of Jun 19 |  +0.56 / +8.76%Today’s Change | 3.03 Today|||52-Week Range 7.00 | +85.33% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP -- |
Company Description
Fibrocell Science, Inc. is an aesthetic and therapeutic development stage company, which is focused on developing novel skin and tissue rejuvenation products. The company's clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient's own, or autologous, fibroblast cells produced by its proprietary Isolagen process. Its clinical development programs encompass both aesthetic and therapeutic indications. The company operates through two reportable segments: Fibrocell Therapy and Agera. The Fibrocell Therapy segment specializes in the development and commercialization of autologous cellular therapies for soft tissue regeneration. The Agera segment maintains proprietary rights to a scientifically-based advanced line of skincare products. Fibrocell Science was founded on September 1, 2009 and is headquartered in Exton, PA.
Employees
Shareholders
| Mutual fund holders | 0.66% |
| Individual stakeholders | -- |
| Other institutional | -- |
Top Executives
| David Pernock | Chairman, President & Chief Executive Officer |
| Declan Daly | Chief Operating & Financial Officer |
| Karen Donhauser | Vice President-Quality |
| John Maslowski | Vice President-Operations |
| Elizabeth A. Browning | Executive Vice President-Marketing & Sales |
.
